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Abstract
Introduction Heparin-induced thrombocytopenia is an immune-
mediated adverse drug reaction that is associated with a
procoagulant state and both arterial and venous thrombosis.
After observing two cases of repeated hemofiltration-filter
clotting associated with high anti-PF4/heparin antibody
concentrations, we systematically measured the anti-PF4/
heparin antibody concentration in all cases of unexpected and
repeated hemofiltration-filter clotting during continuous veno-
venous hemofiltration (CVVH). The aim of this study was to
identify factors associated with positive anti-PF4/heparin
antibody in the case of repeated hemofiltration-filter clotting.
Methods We reviewed the charts of all patients who had an
anti-PF4/heparin antibody assay performed for repeated
hemofiltration-filter clotting between November 2004 and May
2006 in our surgical intensive care unit. We used an enzyme-
linked immunoabsorbent assay (heparin-platelet factor 4-
induced antibody) with an optical density (OD) of greater than 1
IU considered positive.
Results During the study period, anti-PF4/heparin antibody
assay was performed in 28 out of 87 patients receiving CVVH.
Seven patients were positive for anti-PF4/heparin antibodies
(OD 2.00 [1.36 to 2.22] IU) and 21 were antibody-negative (OD
0.20 [0.10 to 0.32] IU). Baseline characteristics, platelet counts,
and activated partial thromboplas t i n  t i m e  r a t i o s  w e r e  n o t
different between the two groups. CVVH duration was
significantly decreased in antibody-positive patients (5.0 [2.5 to
7.5] versus 12.0 [7.5 to 24.0] hours; P = 0.007) as was CVVH
efficiency (urea reduction ratio 17% [10% to 37%] versus 44%
[30% to 52%]; P = 0.04) on heparin infusion. Anti-PF4/heparin
antibody concentration was inversely correlated with CVVH
duration. The receiver operating characteristic curve showed
that a 6-hour cutoff was the best CVVH session duration to
predict a positive antibody test (sensitivity 71%, specificity
85%, and area under the curve 0.83). CVVH duration (32 [22 to
37] hours; P < 0.05) and urea reduction (55% [36% to 68%];
P < 0.03) were restored by danaparoid sodium infusion.
Conclusion Repeated hemofiltration-filter clotting in less than 6
hours was often associated with the presence of anti-PF4/
heparin antibodies, regardless of the platelet count. In antibody-
positive patients, replacement of heparin by danaparoid sodium
allowed the restoration of CVVH duration and efficiency.
Introduction
Heparin-induced thrombocytopenia (HIT) is an antibody-medi-
ated adverse effect of heparin. The initial description con-
cerned arterial thrombosis during unfractionated heparin
(UFH) therapy [1]. HIT subsequently has been associated with
an increased risk of venous or arterial thrombosis [2-4]. The
pathophysiology of HIT consists of the generation of anti-PF4/
heparin antibodies, resulting in platelet and endothelial cell
activation, leading to a procoagulant state [5]. Continuous
veno-venous hemofiltration (CVVH) is widely used for renal
replacement. Because UFH often is used as anticoagulation
therapy, patients undergoing CVVH might be at risk for anti-
aPTT = activated partial thromboplastin time; CVVH = continuous veno-venous hemofiltration; HIT = heparin-induced thrombocytopenia; ICU = inten-
sive care unit; OD = optical density; PF4- = anti-PF4/heparin antibody-negative; PF4+ = anti-PF4/heparin antibody-positive; PRP = platelet-rich 
plasma; ROC = receiver operating characteristic; UFH = unfractionated heparin.Critical Care    Vol 12 No 3    Lasocki et al.
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PF4/heparin antibody generation or HIT. One clinical feature
of HIT in this context could be repeated hemofiltration-filter
clotting [6,7]. In our surgical intensive care unit (ICU), we
recently observed two cases of HIT responsible for repeated
hemofiltration-filter clotting in the absence of typical thrombo-
cytopenia [8] and we then systematically measured the
plasma anti-PF4/heparin antibody concentration in all patients
with repeated hemofiltration-filter clotting during CVVH, with
no obvious cause. The purpose of this study was to report a
series of patients in whom an anti-PF4/heparin antibody test
was performed and to identify factors associated with a posi-
tive test in this particular setting in order to determine when
one should perform the test.
Materials and methods
Patients
Between 1 November 2004 and 1 May 2006, 87 patients
underwent CVVH. Twenty-eight of these patients experienced
repeated (≥ 2) hemofiltration-filter clotting before the sched-
uled end of the CVVH session (24 to 48 hours) with no obvi-
ous cause and anti-PF4/heparin antibodies were assayed. We
reviewed the charts of these 28 patients. In accordance with
French law, because of the retrospective nature of the study,
no written consent was requested. The study was approved by
our institutional review board. For each patient, general char-
acteristics, platelet counts at various time points (admission,
nadir [lowest reported concentration], day of anti-PF4/heparin
antibody assay, and maximal count), and CVVH session dura-
tion and efficiency (assessed by the urea reduction ratio
before/after each session) were recorded. The duration of
CVVH sessions was obtained from the CVVH surveillance
sheet, on which nurses routinely recorded data on an hourly
basis. For each patient, an objective clinical probability scoring
system was used to calculate the likelihood of HIT according
to the Four T-score [9]. For this purpose, we attributed 1 point
for the third item, 'Thrombosis', considering that the hemofiltra-
tion-filter clotting was equivalent to a 'recurrent thrombosis'.
Continuous veno-venous hemofiltration settings
CVVH was performed using the Aquarius system (Aquarius;
Edwards Lifesciences, Maurepas, France). Blood flow was set
at 250 to 300 mL/minute, ultrafiltrate flow at 35 mL/kg per
hour, and substitution solutions (Hemosol® or Prismasol®;
Hospal, Lyon, France) were delivered 1/3 pre-filter and 2/3
post-filter. A dual-lumen 11.5-French catheter (Mahurkar™;
Tyco Healthcare, Wollerau, Switzerland) was inserted into
either the femoral or right internal jugular vein. To exclude cath-
eter dysfunction, catheters were changed in all patients at
least once before anti-PF4/heparin antibody assay.
Anticoagulation management
Before starting the CVVH session, the hemofiltration circuit
was heparinized by priming with 10,000 IU of UFH (Héparine
Choay®; Sanofi-Synthélabo, Paris, France) in 2,000 mL of
saline solution. UFH then was continuously infused in the
hemofiltration circuit to obtain an activated partial thrombo-
plastin time (aPTT) ratio ranging between 1.2 and 2. The aPTT
ratios were measured systematically from the arterial line. In
the case of a positive PF4 test, UFH was replaced by danapar-
oid sodium (Orgaran®; Organon SA, Eragny-sur-Epte, France)
using the manufacturer's recommendations to obtain a spe-
cific danaparoid anti-Xa activity of between 0.4 and 0.6 IU/mL.
PF4 test and heparin-induced platelet activation assay
Anti-PF4/heparin antibodies were measured by enzyme-linked
immunoabsorbent assay (heparin-platelet factor 4-induced
antibody, HPIA; Diagnostica Stago, Asnières, France) accord-
ing to the manufacturer's recommendations. The anti-PF4/
heparin antibody was considered positive (PF4+) when optical
densities (ODs) were greater than 1 IU. For anti-PF4/heparin
antibody-positive patients, a platelet-rich plasma (PRP) aggre-
gation assay was performed. Briefly, a plasma sample was
incubated with donor PRP and a therapeutic (0.5 to 1 IU/mL)
or high (100 IU/mL) UFH concentration in an aggregometer
(Chronolog 490; Kordia Life Sciences, Leiden, The Nether-
lands) at 37°C. Platelet aggregation was monitored for 20
minutes. Results were considered positive if the aggregation
was greater than or equal to 20% with a therapeutic UFH con-
centration and absent with a high UFH concentration. Appro-
priate positive and negative controls (stored patient plasma)
were run in parallel with plasma samples. Cross-reactivity with
danaparoid sodium was recorded under the same conditions.
Statistical analysis
Data are presented as median (interquartile range) and com-
pared with a Mann-Whitney or a chi-square test. Patients were
classified into two groups (PF4+ and PF4-) according to anti-
PF4/heparin antibody concentration. For PF4+ patients, dura-
tion and efficiency of CVVH sessions under UFH and danapar-
oid were compared with a Wilcoxon rank test. A receiver
operating characteristic (ROC) curve was used to determine
the best cutoff value for CVVH duration to predict a PF4+ test.
All statistics were performed with the MedCalc® software
(MedCalc Software, Mariakerke, Belgium). A P value of less
than 0.05 was considered significant.
Results
Patients' characteristics
Among the 28 patients with unexplained hemofiltration-filter
clotting, seven were anti-PF4/heparin antibody-positive. Base-
line characteristics were not different between the two groups
(PF4+ or PF4-), except for a higher SAPS II (Simplified Acute
Physiologic Score II) for PF4- patients (Table 1). None of the
patients had a Four T-score of less than 4, indicating that they
all had an intermediate or high pre-test probability of HIT. A
Four T-score of at least 7 had a positive predictive value of
100% and a negative one of 84% for the diagnosis of HIT, with
a sensitivity of 43%. Four of the seven PF4+ patients (Table 1,
#1–4) also had a positive PRP aggregation assay and may be
considered as having a very likely diagnosis of HIT [2,6].A
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Table 1
Characteristics of the study population
Time to onset, days Platelet counts, 109/L aPTT ratios
Patient Gender Age, years SAPS II SOFA 
score
Type of 
surgery
Sepsis Shock MV ICU CVVH UFH ICU length of 
stay, days
D0 DPF4 Four 
T-score
Mean ≥ 1.2, % CVVH duration, 
hours
PF4, OD Death
PF4+ 1 M 54 34 12 Cardiac No Yes Yes 8 6 8 22 42 10 5 1.2 50 14 1.18 No
2 M 59 29 6 Cardiac No No No 6 6 9 13 76 51 7 1.2 100 2 2.26 No
3 M 63 50 13 Cardiac Yes Yes Yes 9 8 9 28 101 20 7 1.3 33 4 2.68 No
4 F 49 44 11 Cardiac No Yes Yes 7 7 8 8 251 95 7 1.2 33 6 1.89 Yes
5 M 62 86 16 Trauma Yes Yes Yes 15 13 14 22 163 66 5 2.4 100 5 1.18 Yes
6 M 55 52 12 Cardiac No Yes Yes 10 8 11 26 144 200 4 1.9 100 2 2.00 No
7 M 57 42 14 Cardiac Yes Yes Yes 16 15 20 43 78 46 5 2.6 100 8 2.11 No
Total 
(n = 7)
6 M 
(86%)
57 
(55–62)
44a 
(36–51)
12.5 
(12–14)
6 cardiac 
(86%)
3 
(43%)
6 
(86%)
6 
(86%)
9 
(8–15)
8 
(6–13)
9 
(9–14)
22 
(18–28)
101 
(77–158)
51 
(26–88)
5 (5–7) 1.3 
(1.2–2.4)
100 
(50–100)
5a 
(2.5–7.5)
2.00a 
(1.36–2.22)
2 
(40%)
PF4- 8 F 78 64 11 Visceral Yes Yes Yes 4 2 5 4 109 48 6 3.1 100 19 0.11 Yes
9 M 51 51 8 Visceral Yes Yes Yes 5 5 5 16 413 234 6 1.6 75 4 0.19 No
10 M 58 65 19 Cardiac Yes Yes Yes 3 2 10 26 214 42 6 1.2 67 10 0.40 No
11 M 77 68 15 Cardiac Yes Yes Yes 14 14 24 47 176 52 5 1.8 100 12 0.13 Yes
12 M 78 56 16 Cardiac No Yes Yes 4 4 5 15 100 22 5 1.7 100 12 0.26 Yes
13 M 83 89 18 Cardiac Yes Yes Yes 4 3 5 28 86 33 6 1.8 100 9 0.17 Yes
14 M 78 59 11 Cardiac Yes Yes Yes 5 2 4 14 141 31 6 1.8 100 10 0.07 Yes
15 M 37 35 14 Trauma Yes Yes Yes 9 7 7 25 146 63 4 1.1 25 7 0.09 No
16 F 73 62 15 Cardiac Yes Yes Yes 36 36 39 50 94 48 5 3.9 100 24 0.29 Yes
17 M 79 59 10 Visceral Yes Yes Yes 9 9 9 12 169 86 6 1.4 100 31 0.18 Yes
18 M 60 49 10 Cardiac No No Yes 5 3 5 14 60 39 5 1.3 100 24 0.09 No
19 M 48 48 8 Visceral Yes Yes Yes 6 2 9 27 258 167 6 1.8 100 24 0.08 Yes
20 F 75 54 11 Visceral Yes Yes Yes 6 4 7 12 86 21 6 1.9 100 4 0.34 Yes
21 M 60 39 13 Cardiac No Yes Yes 4 3 5 58 61 47 6 1.5 100 24 0.19 No
22 M 75 56 13 Cardiac Yes Yes Yes 19 17 20 37 105 45 5 1.2 25 8 0.83 Yes
23 M 78 57 13 Cardiac Yes Yes Yes 5 4 6 61 67 44 6 1.0 0 13 0.02 No
24 M 64 73 14 Visceral No Yes Yes 16 16 16 26 206 95 6 1.4 100 16 0.24 No
25 M 38 71 20 Vascular Yes Yes Yes 4 4 4 33 210 49 6 1.7 100 18 0.20 No
26 M 69 66 13 Cardiac Yes Yes Yes 5 4 5 11 140 48 6 1.1 25 6 0.51 Yes
27 F 37 52 13 Cardiac Yes Yes Yes 6 5 9 27 57 234 6 1.4 100 7 0.58 No
28 M 75 44 10 Visceral Yes Yes Yes 22 20 24 53 203 42 5 1.4 86 24 0.29 Yes
Total 
(n = 21)
17 M
(81%)
73 
(56–78)
57 
(50–65)
13 
(10–15)
12 cardiac 
(57%)
17 
(81%)
20 
(95%)
21 
(100%)
5 
(4–9)
4 
(3–10)
7 
(5–12)
26 
(14–39)
140 
(86–204)
48 
(41–69)
6 
(5–6)
1.5 
(1.3–1.8)
100 
(73–100)
12 
(7.5–24)
0.20 
(0.10–0.32)
12 
(57%)
Patients were classified into two groups (PF4+ and PF4-) according to anti-PF4/heparin antibody concentration (optical density [OD] > 1 IU or not). PF4+ patients 1 to 4 also had a positive functional test for heparin-induced thrombocytopenia (platelet-rich plasma 
aggregation test). No differences between these four patients and the remaining three patients with a negative functional test were observed. The types of surgery for the two trauma patients were orthopedic and visceral for patient 5 and visceral surgery only for patient 15. 
Shock was defined as the need for vasopressor support. Time to onset is the time between intensive care unit (ICU) admission or continuous veno-venous hemofiltration (CVVH) or unfractionated heparin (UFH) and the day of anti-PF4/heparin antibody assay. The Four T-
score was calculated by considering that hemofiltration-filter clotting did constitute a 'recurrent thrombosis' (= 1 point) [9]. Results are expressed as median (first quartile to third quartile) or number. aP < 0.05. M, male; F, female; aPTT, activated partial thromboplastin time 
(observed during the continuous veno-venous hemofiltration session with hemofiltration-filter clotting); D0, day of admission; DPF4, day of anti-PF4/heparin antibody assay; MV, mechanical ventilation; PF4-, anti-PF4/heparin antibody-negative; PF4+, anti-PF4/heparin antibody-
positive; SAPS II, Simplified Acute Physiologic Score [19]; SOFA, Sepsis-related Organ Failure Assessment [20].Critical Care    Vol 12 No 3    Lasocki et al.
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Among the seven patients with HIT, two also had a vascular
thrombosis, leading to the diagnosis of HITTS (heparin-
induced thrombocytopenia and thrombosis syndrome): one
had an ischemic stroke (#4) and the other one a pulmonary
embolism (#5).
Platelet counts
The platelet counts and platelet count variations did not differ
between the two groups at any time point (Tables 1 and 2). In
four patients (one PF4+ and three PF4-), the platelet count was
higher than 100 × 109/L the day of the anti-PF4/heparin anti-
body test (Table 1).
Continuous veno-venous hemofiltration sessions
The main CVVH session characteristics are summarized in
Tables 1 and 2. No significant difference was observed in
terms of aPTT ratios, regardless of the value considered. The
duration of CVVH sessions was significantly decreased in
PF4+ patients (Table 1; P = 0.007). An inverse correlation was
observed between the anti-PF4/heparin antibody concentra-
tion (OD) and the duration of CVVH sessions (r2 = 0.24; P =
0.01). As CVVH session duration was the only parameter
associated with positive antibodies, we assessed the most rel-
evant duration to predict a positive test. The ROC curve anal-
ysis showed that 6 hours was the best cutoff to predict a
positive anti-PF4/heparin antibody test (with a sensitivity of
71%, a specificity of 85%, and an area under the curve of
0.83) (Figure 1). The efficiency of CVVH sessions (assessed
by the urea reduction ratio) was also decreased in PF4+
patients (Figure 2). The use of danaparoid sodium as a
replacement for UFH allowed the restoration of adequate
CVVH duration (32 [22 to 37] hours; P < 0.05) and efficiency
(urea reduction 55% [36% to 68%]; P  < 0.03) for PF4+
patients (Figure 2).
Discussion
Repeated hemofiltration-filter clotting leading to anti-PF4/
heparin antibody assay is frequent in our experience. We
report a large proportion of patients with positive anti-PF4/
heparin antibodies (7 out of 28). A CVVH session lasting less
than 6 hours was associated with positive antibodies. As the
aim of this study was not to assess the prevalence of HIT or
positive anti-PF4/heparin antibodies in our overall ICU popula-
tion, we did not measure anti-PF4/heparin antibody for
patients without hemofiltration-filter clotting. However, it is
unlikely that 'unselected' patients would have a high rate of
positive anti-PF4/heparin antibodies. Indeed, the incidence of
HIT in intensive care patients is about 1% [6,10]. Furthermore,
to our knowledge there are no data in the literature to support
routine anti-PF4/heparin antibody assays without a clinical
suspicion of HIT or thrombosis/clotting on heparin therapy
[2,6].
We and others have already described cases of repeated
hemofiltration-filter clotting associated with positive anti-PF4/
heparin antibodies [7,8]. However, such a large proportion of
patients with positive anti-PF4/heparin antibodies was not
expected and has not been previously reported. In their large
cohort of 2,046 post-operative critically ill patients, Gettings
and colleagues [10] reported only 19 (0.9%) patients with
positive anti-PF4/heparin antibodies. The presence of positive
Table 2
Laboratory and continuous veno-venous hemofiltration (CVVH) parameters
PF4+ (n = 7) PF4- (n = 21) P value
Creatinine before first CVVH, μmol/L 600 (247–742) 403 (312–441) 0.34
Urea before first CVVH, mmol/L 17 (10–25) 15 (12–24) 0.91
Number of CVVH sessions 5 (4–11) 5 (3–9) 0.65
Mean CVVH durationa, hours 10.4 (9.6–18–4) 22.7 (15.7–22.3) 0.03
Mean urea reduction ratiosa, percentage 17 (10–37) 44 (30–52) 0.04
Platelet nadir, 109/L 40 (24–46) 35 (17–43) 0.54
Maximum platelet count, 109/L 324 (238–366) 286 (182–403) 0.81
PF4 platelet count variation (D0-DPF4), percentage 59 (35–73) 56 (35–73) 0.98
Maximum platelet count variation (D0-Dnadir), percentage 77 (49–81) 79 (55–87) 0.81
Mean minimum aPTT ratiosb 1.20 (1.12–1.22) 1.35 (1.10–1.56) 0.35
Mean maximum aPTT ratiosb 1.85 (1.65–2.12) 2.19 (1.51–2.93) 0.35
Platelet count variations were calculated as follows: [(platelet D0 – platelet Dx)/platelet D0] × 100, where platelet D0 is the platelet count on 
admission and platelet Dx is the platelet count on the day of anti-PF4/heparin antibody assay (DPF4) or the minimal platelet count (Dnadir). Results 
are expressed as median (first quartile to third quartile). aFor PF4+ patients, mean duration and efficiency of CVVH sessions before replacement of 
unfractionated heparin by danaparoid; bmeans of minimum and maximum aPTT ratios observed during all the CVVH sessions before DPF4. aPTT, 
activated partial thromboplastin time (on heparin therapy during all continuous veno-venous hemofiltration sessions); PF4-, anti-PF4/heparin 
antibody-negative; PF4+, anti-PF4/heparin antibody-positive.Available online http://ccforum.com/content/12/3/R84
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antibodies may be an independent risk factor for thrombotic
events, apart from the diagnosis of HIT [11], as anti-PF4/
heparin antibodies are associated with dose-dependent acti-
vation of coagulation [12]. We therefore decided to use a high
cutoff value for positive antibody OD (> 1 IU). It should be
emphasized that the anti-PF4/heparin antibody OD observed
in our patients was inversely correlated with the CVVH session
duration. The time to onset of hemofiltration-filter clotting
appeared to be shorter in patients with higher anti-PF4/
heparin antibody titer, possibly indicating more intense activa-
tion of coagulation.
Despite the high cutoff chosen to define positive antibodies, a
large number of patients presented positive antibodies. This is
probably related to our study population as the probability of
HIT (or positive anti-PF4/heparin antibodies) depends on the
population studied [2,9,13]. In our study, patients were highly
selected and represented less than one third of all patients
undergoing CVVH in our unit. Furthermore, complicated car-
diac surgery patients account for the majority of our case mix
and, together with orthopedic patients, are known to present
the highest risk of positive anti-PF4/heparin antibodies
[2,14,15].
We do not assume that all seven anti-PF4/heparin antibody-
positive patients had true HIT, but the diagnosis of HIT was
very likely in four of these seven patients and was probable in
the remaining three patients according to published criteria
[6]. Furthermore, a strong positive test result (OD > 1) is asso-
ciated with a high likelihood ratio for HIT [2]. The diagnosis of
HIT is based on two aspects: clinical features, including the
course of platelet count (with a greater than 50% decrease
over a typical time scale [16]), and laboratory features, includ-
ing confirmation tests [2,17]. In our study population, the tim-
ing of HIT suspicion was within the usual range. Moreover, the
Four T-scores [9], though not validated for ICU patients, indi-
cated at least an intermediate risk for all patients. Although
thrombocytopenia is the most common feature of HIT, it is also
a very common finding in ICU patients and could be related to
many causes, including CVVH itself. In fact, platelet counts
were low in both groups (PF4+ and PF4-). The time to clotting
of the hemofiltration-filter therefore appeared to be the only
factor associated with positive anti-PF4/heparin antibodies.
Figure 1
Receiver operator characteristic curve for continuous veno-venous  hemofiltration (CVVH) duration Receiver operator characteristic curve for continuous veno-venous 
hemofiltration (CVVH) duration. A receiver operating characteristic 
curve was used to assess the best cutoff for time to hemofiltration-filter 
clotting to predict a positive PF4 test. The arrow shows that a 6-hour 
duration of CVVH session is the most accurate cutoff (sensitivity 71%, 
specificity 85%, and area under the curve 0.83).
Figure 2
Duration and efficiency of continuous veno-venous hemofiltration  (CVVH) sessions Duration and efficiency of continuous veno-venous hemofiltration 
(CVVH) sessions. Boxes represent medians, interquartile ranges, and 
10th and 90th percentiles of mean duration of CVVH sessions (upper 
panel) and urea reduction ratios ([(urea before – urea after)/urea 
before] × 100, lower panel) observed in PF4+ (n = 7) and PF4- (n = 21) 
patients when using unfractionated heparin (50 and 132 sessions for 
PF4+ and PF4- patients, respectively) and in PF4+ patients when using 
danaparoid sodium for anticoagulation (17 sessions). *P < 0.05 com-
pared with PF4+ (using a Mann-Whitney test); #P = 0.027 compared 
with PF4+ (using a Wilcoxon rank test). There was no difference 
between PF4- and danaparoid CVVH durations (P = 0.17) or urea 
reduction (P = 0.27). PF4-, anti-PF4/heparin antibody-negative; PF4+, 
anti-PF4/heparin antibody-positive.Critical Care    Vol 12 No 3    Lasocki et al.
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Interestingly, the 6-hour cutoff reported here is consistent with
the 7.5-hour interval before clotting observed by Samuelsson
and colleagues [7].
Finally, although the diagnosis of HIT was not certain for all
anti-PF4/heparin antibody-positive patients, replacement of
UFH by danaparoid sodium allowed the restoration of CVVH
duration and efficiency, supporting the clinical relevance of
anti-PF4/heparin antibody assay in the case of repeated
hemofiltration-filter clotting, at least in a surgical ICU patient
population. Interestingly, the durations of CVVH sessions
under danaparoid sodium we observed were close to those
described by de Pont and colleagues [18]. In accordance with
the latter authors, we did not observe any bleeding complica-
tions during danaparoid therapy. Furthermore, once the
diagnosis of HIT is considered, all heparin exposure, including
intravenous catheter locks, should cease.
Because of the retrospective nature of the study, we are not
able to precisely determine the causes of hemofiltration-filter
clotting in the remaining 21 patients with negative anti-PF4/
heparin antibody. In particular, we did not perform PRP aggre-
gation assays or serotonin release assays to search for HIT
with an antigenic target different from PF4, nor did we assess
the anti-thrombin III levels of these patients, but they had ele-
vated aPTT ratios, indicating a certain activity of UFH. Further
studies focusing on hemofiltration-filter clotting are needed to
better describe this issue and the different factors associated
with filter clotting (such as coagulation activation or abnormal-
ities as well as CVVH settings or catheter dysfunction).
Conclusion
We report a large proportion of anti-PF4/heparin antibody-
positive patients in the case of repeated hemofiltration-filter
clotting during CVVH, particularly when clotting occurred in
less than 6 hours. In these cases, replacement of UFH by dan-
aparoid sodium (or other agents such as citrate or saline
flushes) may be useful.
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